- Senate passes Drug Quality and Security Act
- NACDS RxImpact shines spotlight on pharmacists' increasing role in delivery of healthcare services
- Study: Higher levels of sleep aid melatonin may reduce prostate cancer risk
- CDC publishes guidelines for collaborative practice agreements
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
WASHINGTON — A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial.
Data from the phase-2 study of the drug Rapaflo (silodosin) presented at the American Urological Association’s annual meeting showed that it reduced symptoms and improved outcomes in men with chronic prostatitis/pelvic pain syndrome, also known as CP/CPPS.
CP/CPPS is a common condition that causes persistent discomfort in the lower pelvic area, frequent and painful urination and difficult or painful ejaculation. The cause of the condition is unknown, but is not related to bacterial infection. As many as 10% of men in North America have had or will have experienced prostatitis symptoms, and 90% of those have CP/CPPS.